Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2195)	1/23/2008 9:36:39 AM
From: Jibacoa	Respond to of 3722

ABT opened down 1% in spite of reporting earnings in line with its previous guidance.<g> stockcharts.com ABT 4thQ earnings were as expected, $1.20B ($0.77) vs, loss of $476M ($0.31) in 2006 when it reported charges related to its purchase of Kos. Excluding special items,ABT earnings were $0.93/shr.(Its forecast was around $0.91 to $0.93) It is expected that sales of Humira will rise to $4B in 2008, as the drug continues to compete against JNJ's Remicade & WYE's Enbrel. Bernard